Skip to Main Content

WASHINGTON — The Food and Drug Administration doesn’t have enough funding or staff to properly regulate pharmaceutical compounders, a top agency official said Friday, describing inspections that turned up “stuff floating around” in supposedly sterile shipments.

The program doesn’t “have adequate core staffing,” said Janet Woodcock, director of the Center for Drug Evaluation and Research, on Friday, adding that it’s one of the center’s programs that is “suffering the most.”

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED
  • I am a retired health care professional and I remain very interested in the
    areas of prescrip drug development and pricing and need for tighter regs
    over pharm development and physician scripts for meds not specifically
    approved for treatment of certain diagnoses. Impurities critical !

  • The FDA has utterly failed in it’s mission to protect public health. They chose to ignore this problem, even after all of those patents were injected with fungus tainted steroids. When Industry insiders decide where the regulations should be removed, while Congress under-funds necessary services, they are unable to function in the way they were intended to. This is what happens when science and facts are ignored to increase profitability.

Comments are closed.